clinical trial · NCT05030350
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
Social Anxiety DisorderPH94B
brief summary
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily life. Safety and tolerability of PH94B (≤ 4 doses per day up to 12 months) will be assessed and summarized during monthly visits from baseline (Visit 2) to end of treatment (Visit 14) in AEs, laboratory values, 12-lead ECGs, physical examinations, and vital sign assessments following exposure to PH94B.
started
Oct 1, 2021
primary completion
Sep 23, 2022
completion
Sep 23, 2022
last updated
Oct 21, 2025
official title
A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol